| abstract |
A method of treating an IL-12 / 23 related disease in a patient using an increasing dosing interval is to increase the dosing interval of the IL-12 / IL-23 antibody to the patient, the antibody first being Administered and administered four weeks, sixteen weeks, and twenty-eight weeks, increasing and after 28 weeks, the dosing interval, for example, once every 16, 20, or 24 weeks And increasing. |